

**PRIOR AUTHORIZATION REQUEST FORM**

BMCHP Antibiotics (Systemic) - Policy 9.108 (2)  
 Xifaxan

**Phone: 888-566-0008 Fax back to: 866-414-3453**

ENVISION RX OPTIONS manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

**Patient Name:**

Member/Subscriber Number:  
 Date of Birth:  
 Group Number:  
 Address:  
 City, State ZIP:  
 Primary Phone:

**Prescriber Name:**

Fax: Phone:  
 Office Contact:  
 NPI: State Lic ID:  
 Address:  
 City, State ZIP:  
 Specialty/facility name (if applicable):

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

**Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.**

Q1. Is the request for initial or continuing therapy?

- Initial therapy (Start date MM/YY):
- Continuing therapy

Q2. Please specify the medication requested:

- Xifaxan 200 mg Tablets
- Xifaxan 550 mg Tablets

Q3. Please indicate the diagnosis below:

- Traveler's Diarrhea caused by non-invasive strains of E. coli
- Hepatic Encephalopathy
- Diarrhea predominant irritable bowel syndrome (IBS) with bloating
- Other (please specify):

Q4. Please indicate the medication(s) tried and failed, experienced intolerance, contraindication to, or resistance to. Please specify all drug names and describe the inadequate response, intolerance, or contraindication to treatment for each one below:

- Ciprofloxacin, please specify: \_\_\_\_\_
- Azithromycin, please specify: \_\_\_\_\_
- Lactulose, please specify: \_\_\_\_\_

**PRIOR AUTHORIZATION REQUEST FORM**

BMCHP Antibiotics (Systemic) - Policy 9.108 (2)  
Xifaxan

**Phone: 888-566-0008 Fax back to: 866-414-3453**

ENVISION RX OPTIONS manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

**Patient Name:**

**Prescriber Name:**

- Antispasmodic: \_\_\_\_\_, please specify: \_\_\_\_\_
- Tricyclic antidepressant: \_\_\_\_\_, please specify: \_\_\_\_\_
- Dietary changes such as restriction of lactose, fructose, gas-producing foods, or caffeine, please specify: \_\_\_\_\_

Q5. Is the patient 18 years or older?

- Yes                       No

Q6. Please provide any supporting clinical statements (e.g. chart notes, lab values, adverse outcomes, treatment failures, or any other additional clinical information) to support an authorization request

\_\_\_\_\_  
Prescriber Signature

\_\_\_\_\_  
Date

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document.

This transmission may contain protected health information, which is transmitted pursuant to an authorization or as permitted by law. The information herein is confidential and intended only for use by the designated recipient who/which must maintain its confidentiality and security. If you are not the designated recipient, you are strictly prohibited from disclosing, copying, distributing, or taking action in reliance on the contents hereof. If you have received this transmission in error, please notify the sender immediately and arrange for the return or destruction of all of its contents. Unauthorized redisclosure of confidential health information is prohibited by state and federal law.